2023
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Castro M, Wilkinson S, Al Jurdi R, Petrillo M, Zaki N, Borentain S, Fu D, Turkoz I, Sun L, Brown B, Cabrera P. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study. CNS Drugs 2023, 37: 715-723. PMID: 37558912, PMCID: PMC10439056, DOI: 10.1007/s40263-023-01026-3.Peer-Reviewed Original ResearchConceptsEsketamine nasal spraySUSTAIN 1Nasal spraySecond inductionMaintenance treatmentMADRS response ratesTreatment-emergent AEsDepression rating scoresNew safety signalsTreatment-resistant depressionTime of relapseLong-term treatmentLong-term trialsEligible patientsOral antidepressantsRemission rateStable remissionSubgroup analysisChronic illnessSafety signalsInterim analysisDepressive symptomsPatientsResponse rateRemission
2021
Mental Health Care Resource Utilization and Barriers to Receiving Mental Health Services Among US Adults With a Major Depressive Episode and Suicidal Ideation or Behavior With Intent.
Voelker J, Cai Q, Kuvadia H, Daly E, Connolly N, Pesa J, Sheehan J, Wilkinson S. Mental Health Care Resource Utilization and Barriers to Receiving Mental Health Services Among US Adults With a Major Depressive Episode and Suicidal Ideation or Behavior With Intent. The Journal Of Clinical Psychiatry 2021, 82 PMID: 34529898, DOI: 10.4088/jcp.20m13842.Peer-Reviewed Original ResearchConceptsMajor depressive episodeMental health servicesHealth care resource utilizationHealth servicesSuicidal ideationDepressive episodeMental health treatmentLogistic regression modelsPrescription medicationsOutpatient careInpatient careHigher oddsExtensive burdenHealth treatmentUnmet needDrug useCohortCareAdult participantsNational surveyIdeationRegression modelsGreatest barrierTreatmentEpisodes
2018
Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital.
Wilkinson ST, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G. Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. The Journal Of Clinical Psychiatry 2018, 79 PMID: 30063304, PMCID: PMC6296748, DOI: 10.4088/jcp.17m11731.Peer-Reviewed Original ResearchConceptsMood disordersClinical treatmentTreatment-resistant mood disordersResearch protocolLong-term adverse effectsRapid-acting antidepressantsLong-term safetyEmergence of symptomsRemission rateKetamine infusionFourth infusionLabel therapyTerm outcomesAuthors' institutionPsychiatric hospitalTotal infusionPatientsCognitive declineKetamineTotal treatmentInfusionAdverse effectsClinical samplesLong-term basisTreatmentIdentifying Recipients of Electroconvulsive Therapy: Data From Privately Insured Americans
Wilkinson ST, Agbese E, Leslie DL, Rosenheck RA. Identifying Recipients of Electroconvulsive Therapy: Data From Privately Insured Americans. Psychiatric Services 2018, 69: 542-548. PMID: 29385954, PMCID: PMC6248332, DOI: 10.1176/appi.ps.201700364.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyMood disordersClinical characteristicsECT useUse of ECTCharacteristics of patientsProportion of patientsComorbid psychiatric disordersMajor depressive disorderNumber of prescriptionsSubstance use disordersOutpatient psychotherapy visitsECT patientsECT utilization rateMarketScan databasePsychotherapy visitsPsychotropic medicationsDepressive disorderPsychiatric disordersService useUse disordersPatientsECT utilizationBipolar disorderCommercial insurance
2017
Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression
Wilkinson ST, Wright D, Fasula MK, Fenton L, Griepp M, Ostroff RB, Sanacora G. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression. Psychotherapy And Psychosomatics 2017, 86: 162-167. PMID: 28490030, PMCID: PMC5516265, DOI: 10.1159/000457960.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAdultAntidepressive AgentsCognitionCognitive Behavioral TherapyCombined Modality TherapyDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantFemaleHumansKaplan-Meier EstimateKetamineMaleMiddle AgedPsychiatric Status Rating ScalesRecurrenceRemission InductionTreatment OutcomeYoung AdultConceptsTreatment-resistant depressionCognitive behavioral therapyAntidepressant effectsKetamine's antidepressant effectsKetamine exposureIntravenous ketamineKetamine infusion therapyWeeks of protocolOpen-label trialLong-term treatmentStandardized clinical protocolCognitive behavior therapyKetamine nonrespondersKetamine respondersRelapse rateMedian timeInfusion therapyClinical protocolsKetamineNeurobiological changesRemissionBehavioral therapyTherapyWeeksBehavior therapyComputer-Assisted Cognitive Behavior Therapy to Prevent Relapse Following Electroconvulsive Therapy
Wilkinson ST, Ostroff RB, Sanacora G. Computer-Assisted Cognitive Behavior Therapy to Prevent Relapse Following Electroconvulsive Therapy. Journal Of Ect 2017, 33: 52-57. PMID: 27564424, PMCID: PMC5315599, DOI: 10.1097/yct.0000000000000348.Peer-Reviewed Original ResearchConceptsComputer-assisted cognitive-behavior therapyElectroconvulsive therapyCognitive behavior therapyMean timeOpen-label trialMajor depressive episodeMean numberBehavior therapyAcute treatmentDepressive episodeIndex coursePrevent relapseDepression severityRelapsePotential efficacyTherapyMonthsOwn homesPreliminary evidenceRemittersTrialsSubjectsEntire sampleHoursRemission